Combined treatment with photodynamic therapy and chemotherapy for advanced cardiac cancers

J Photochem Photobiol B. 1992 Jan;12(1):101-6. doi: 10.1016/1011-1344(92)85021-l.

Abstract

In all, 144 patients with advanced cardiac cancers have been treated by photodynamic therapy (PDT), combined chemotherapy and chemotherapy alone from September 1982 to July 1990. A total of 5 mg kg-1 haematoporphyrin derivative (HpD) was intravenously given 48-72 h prior to PDT. The light source was an argon dye laser with an output beam of 630 nm. The irradiation time varied between 12 and 25 min with a fluence of 100-350 mW cm-2. The entire tumour was irradiated with a light dose of 100-250 J cm-2. The combination of UFT and mitomycin C was used as standard chemotherapy. There were 26 responders out of 55 patients (47.3%) in the group treated with PDT alone, 24 out of 41 (58.5%) in the PDT+chemotherapy group, and 24 out of 48 (50.0%) in the chemotherapy alone group. In the PDT+chemotherapy group 19.5% patients had complete remission, which was better than the other two groups (5.5%, 8.3%, p less than 0.05). The following survey of all patients lasted from six months to seven years. The results suggest that a combination of PDT and chemotherapy may prove effective.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Combined Modality Therapy
  • Follow-Up Studies
  • Heart Neoplasms / drug therapy*
  • Hematoporphyrin Derivative
  • Hematoporphyrins / therapeutic use*
  • Humans
  • Mitomycin / therapeutic use*
  • Photochemotherapy*
  • Radiation-Sensitizing Agents / therapeutic use*

Substances

  • Hematoporphyrins
  • Radiation-Sensitizing Agents
  • Mitomycin
  • Hematoporphyrin Derivative